PolyTherics, Ltd.: Series C $3.5M

Posted in I - Series C, Q - 3Q11, R - INTERNATIONAL, X - Biochem, X - GlycoBiology

PolyTherics (United Kingdom) a preclinical-stage biochemistry company focused on pegylation technologies, closed a $3.5M Series C financing. Participants include Beringea, Imperial Innovation and The Capital Fund.

Thanx for your patience as we catch-up.

Pharnext, SAS: Series B $3.5M

Posted in I - Series B, Q - 3Q11, R - INTERNATIONAL, X - Charcot-Marie-Tooth, X - Neuromuscular

Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $3.5M Series B financing. Participants include Parinvest Capital, La Financiere Gaspard and Truffle Capital

Thanx for your patience as we catch-up.

Breathe America, Inc.: Series B $22M

Posted in I - Series B, Q - 3Q11, R - SOUTH EAST, X - Allergy, X - Asthma, X - Sinus, XX - TN

Breathe America (Nashville, TN) a commercial-stage clinical company focused on the treatment of chronic airway diseases, allergy, sinus and asthma, closed a $22M Series B financing. Participants include Essex Woodlands.

Thanx for your patience as we catch-up.

Edison Pharmaceuticals, Inc.: Series E $4.1M

Posted in I - Series E, Q - 3Q11, R - WEST, X - Friedreich's Ataxia, X - Mitochondrial, XX - CA

Edison Pharmaceuticals (Mountain View, CA) a clinical-stage small molecule company focused on mitochondrial disease Friedreich’s ataxia, closed a $4.1M Series E financing. Participants were not identified.

Thanx for your patience as we catch-up.

Zafgen, Inc.: Series C $33M

Posted in I - Series C, Q - 3Q11, R - NORTH EAST, X - Obesity, XX - MA

Zafgen (Cambridge, MA) a clinical-stage biopharmaceutical company focused on small molecule therapeutics for the treatment of obesity, closed a $33M Series C financing. Participants include Atlas Venture and Third Rock Ventures.

Thanx for your patience as we catch-up.

Antisense Pharma, GmbH: Series F $11M

Posted in I - Series F, Q - 3Q11, R - INTERNATIONAL, X - Antisense, X - Gene Silencing, X - Oncology

Antisense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $11M Series F financing. Participants include MIG Fonds and Global Asset Fund.

Thanx for your patience as we catch-up.

SeeChange Health, Inc.: Series B $20M

Posted in I - Series B, Q - 3Q11, R - WEST, X - TeleMedicine, XX - CA

SeeChange Health (San Francisco, CA) a commercial-stage health management company focused on data analytics and interactive personal health records, closed a $20M Series B financing. Participants include Maverick Capital and Psilos Group.

Thanx for your patience as we catch-up.

Circle Cardiovascular Imaging, Inc.: Series B $3.9M

Posted in I - Series B, Q - 3Q11, R - INTERNATIONAL, X - Imaging, X - TeleMedicine

Circle Cardiovascular Imaging (Canada) a commercial-stage analytical software company focused on cardiac imaging, closed a $3.9M Series B financing. Participants include Business Development Bank of Canada, Foundation Equity and First Yellowhead Equities.

Thanx for your patience as we catch-up.

SARcode, Inc.: Series B $44M

Posted in I - Series B, Q - 3Q11, R - WEST, X - Dermatology, X - Inflammation, X - Opthalmology, XX - CA

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners.

Thanx for your patience as we catch-up.

Intervention Insights, Inc.: Series B $7.2M

Posted in I - Series B, Q - 3Q11, R - MID WEST, X - Device (Diagnostic), X - Oncology, XX - MI

Intervention Insights (Grand Rapids, MI) a commercial-stage personalized medicine company focused on molecularly targeted oncology therapies, closed a $7.2M Series B financing. Participants include Beringea, Chrysalis Ventures, Hopen Life Science Ventures and Michigan Accelerator Fund.

Thanx for your patience as we catch-up.

« Previous Entries

to top of page...